Journal
MATTER
Volume 1, Issue 5, Pages 1331-1353Publisher
CELL PRESS
DOI: 10.1016/j.matt.2019.06.007
Keywords
-
Categories
Funding
- National Cancer Institute [U01-CA198989, 1R01CA216436]
- University of Chicago Medicine Comprehensive Cancer Center (NIH) [CCSG: P30 CA014599]
- Ludwig Institute for Metastasis Research
- CBI training grant (NIH) [5T32GM008720-15]
Ask authors/readers for more resources
Checkpoint blockade immunotherapy ( CBI) is effective in promoting a systemic immune response against some metastatic tumors. The reliance on the pre-existing immune environment of the tumor, however, limits the efficacy of CBI on a broad spectrum of cancers. Herein, we report the design of a novel nanoscale metal-organic layer (nMOL), Hf-MOL, for effective treatment of local tumors by enabling radiotherapy-radiodynamic therapy (RT-RDT) with low-dose X-rays and, when in combination with an immune checkpoint inhibitor, regression of metastatic tumors by reactivating antitumor immunity and inhibiting myeloid-derived suppressor cells. Owing to the reduced dimensionality, nMOLs allow facile diffusion of reactive oxygen species and exhibit superior RT-RDT effects. The synergy of Hf-MOL-enabled RT-RDT immune activation and anti-programmed death ligand 1 CBI led to robust abscopal effects on a series of bilateral models of colon, head and neck, and breast cancers, as well as significant antimetastatic effects on an orthotopic model of breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available